Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
JAMASep 1, 2026
Maartina J P Oosterom-Eijmael, Abraham H Hulst, Nelson P Monteiro de Oliveira et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, double-blind, placebo-controlled randomized clinical trial evaluated the effect of dapagliflozin on acute kidney injury (AKI) in 784 adults undergoing elective cardiac surgery. The study found that dapagliflozin significantly reduced the incidence of AKI at 7 days post-surgery, with rates of 28% in the dapagliflozin group compared to 52% in the placebo group (relative risk, 0.54; P < .001).
Key findings
- Dapagliflozin reduced AKI incidence to 28% compared to 52% in the placebo group.
- The relative risk of AKI with dapagliflozin was 0.54 (95% CI, 0.45-0.65).
- Atrial fibrillation occurred in 45% of both groups, indicating no difference in this adverse event.
Why it matters
The findings suggest that dapagliflozin may be an effective intervention to reduce the risk of AKI in patients undergoing elective cardiac surgery, a significant concern in postoperative care.